Fruquintinib plus immunotherapy as maintenance therapy for gastric cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two medications—fruquintinib (a targeted therapy) and a PD-1 inhibitor (immunotherapy)—as a first maintenance treatment after initial chemotherapy for advanced gastric cancer. The goal is to see if this combination can help control the cancer longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and in reasonably good health (ECOG score 0-1).
- You have advanced or metastatic gastric or gastroesophageal junction cancer that cannot be removed by surgery.
- You have not had any prior chemotherapy for your advanced cancer.
- Your tumor is MSS/pMMR (meaning it does not have the high microsatellite instability) and HER2 negative.
- You have at least one measurable tumor and good organ function (kidney, liver, blood counts).
- You are able to take oral medication and use effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an oral targeted therapy (fruquintinib), an immunotherapy (PD-1 inhibitor), and chemotherapy (FOLFOX) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this triplet therapy helps control the cancer better than standard treatments.
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.